Mizuho Securities USA LLC Cuts Stake in IQVIA Holdings Inc. (NYSE:IQV)

Mizuho Securities USA LLC lessened its stake in IQVIA Holdings Inc. (NYSE:IQV) by 20.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 11,230 shares of the medical research company’s stock after selling 2,818 shares during the quarter. Mizuho Securities USA LLC’s holdings in IQVIA were worth $2,661,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Versant Capital Management Inc lifted its stake in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after buying an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in IQVIA during the 2nd quarter valued at $27,000. Capital Performance Advisors LLP bought a new stake in shares of IQVIA in the 3rd quarter worth $27,000. Park Place Capital Corp purchased a new position in shares of IQVIA in the third quarter worth $28,000. Finally, Itau Unibanco Holding S.A. bought a new position in shares of IQVIA during the second quarter valued at $29,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Price Performance

NYSE IQV opened at $201.82 on Friday. The stock has a market cap of $36.63 billion, a price-to-earnings ratio of 26.49, a PEG ratio of 2.03 and a beta of 1.51. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company’s 50 day moving average is $222.67 and its two-hundred day moving average is $227.18. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of recent analyst reports. Robert W. Baird decreased their target price on IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research report on Friday, November 1st. Truist Financial lowered their price objective on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. BTIG Research cut their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. reduced their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.